Radiopharm Theranostics (NASDAQ:RADX) Lowered to Strong Sell Rating by Wall Street Zen

Radiopharm Theranostics (NASDAQ:RADX) was downgraded by Wall Street Zen to a “strong sell” rating in a research report issued on Friday.

Several other research firms also recently weighed in on RADX. Weiss Ratings reissued a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Wednesday, October 8th. B. Riley reaffirmed a “buy” rating and set a $16.00 price objective (up previously from $13.00) on shares of Radiopharm Theranostics in a research note on Tuesday, December 16th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $15.33.

Radiopharm Theranostics Trading Down 2.4%

RADX stock opened at $4.93 on Friday. Radiopharm Theranostics has a 12 month low of $3.50 and a 12 month high of $16.25. The company’s 50 day simple moving average is $5.02 and its 200-day simple moving average is $5.32.

Hedge Funds Weigh In On Radiopharm Theranostics

A hedge fund recently bought a new stake in Radiopharm Theranostics stock. PNC Financial Services Group Inc. bought a new position in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,000 shares of the company’s stock, valued at approximately $37,000. PNC Financial Services Group Inc. owned 0.10% of Radiopharm Theranostics at the end of the most recent quarter.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.